Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter open-label phase II trial of trastuzumab in patients with HER2 positive
B-ALL in relapse, or with refractory disease. Herceptin is administered as a 4 mg/kg
intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or till
progression. Response and HER2 expression are assessed each month by bone marrow aspirate.